Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 2/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29937297 | 0.88 | TRPA1 (0.34) | NTRK1TRPA1SCN5ASCN9ALRRK2 | |
| SCHEMBL29937063 | 0.76 | NTRK1 (0.36) | NTRK1TRPA1SCN5ASCN9ALRRK2 | |
| SCHEMBL15540970 | 0.73 | NTRK1 (0.49) | NTRK1NTRK3LRRK2MAPK1 | |
| SCHEMBL29937217 | 0.70 | MAPK1 (0.37) | NTRK1NTRK3MAPK1 | |
| SCHEMBL15542269 | 0.68 | NTRK1 (0.40) | NTRK1TRPA1SCN5ASCN9ANTRK3 | |
| SCHEMBL29937465 | 0.65 | ITK (0.51) | NTRK1LRRK2MAPK1 | |
| SCHEMBL14818880 | 0.65 | MAP2K4 (0.49) | NTRK1LRRK2MAPK1 | |
| SCHEMBL15942805 | 0.65 | ITK (0.51) | NTRK1LRRK2MAPK1 | |
| SCHEMBL25547756 | 0.64 | LRRK2 (0.33) | TRPA1SCN5ASCN9ALRRK2 | |
| SCHEMBL25394366 | 0.63 | NTRK1 (0.38) | NTRK1TRPA1SCN5ASCN9ANTRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| EP-4322954-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2024-02-21 | — | — | EP | disclosed |
| WO-2022221739-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | MERCK SHARP & DOHME CORP. (US) | 2022-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | KRAS, NRAS, HRAS | NTRK1 1885/4885TRPA1 4540/4885SCN5A 1884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.